Publication at First Faculty of Medicine |
2015
Abstract
Strontium ranelate has dual mechanism of action - it enhances bone formation and reduces bone resorption at the same time. Therapy with strontium impacts positively on all determinants of bone strength, that is bone mass, bone volume, microarchitecture and quality.
Strontium ranelate is a drug that relies on evidence-based medicine data including reduced risk of both vertebral and non- vertebral fractures after one, 3, 5 and 8 years of use, including femoral neck fractures. The effect consisting in the reduction of the number of fractures has been shown in extension studies even as late as after 10 years.